Q-Line Biotech Limited

ANNEXURE-V

MATERIAL ADJUSTMENTS [AS PER THE ICDR) REGULATION]

Appropriate adjustments have been made in the restated financial statements, whenever required, by reclassification of the corresponding items of assets, liabilities and cash flow statement, in order to ensure consistency and compliance with requirement of Company Act 2013, and Accounting Standards.

The Summary of results of restatements made in the audited financial statements of the Company for the respective years and their impact on the profit /(losses) of the Company is as under.

Statement of adjustments in the Consolidated Financial Statements

(Amount in Lakhs Rs.)

Statement of Reserves & Surplus

<table><thead><tr><th>Particulars</th><th>31-Mar-25</th><th>31-Mar-24</th><th>31-Mar-23</th></tr></thead><tbody><tr><td>Total Reserve & Surplus as per audited accounts but before adjustments for restated accounts: (a)</td><td>18,837.92</td><td>17,566.62</td><td>13,785.07</td></tr><tr><td>Add: Cumulative Adjustment made in Statement of Profit and Loss Account</td><td>(449.89)</td><td>(1,341.87)</td><td>(923.14)</td></tr><tr><td>Adjustment with the Opening Reserves as on 01-04-2021</td><td>(474.51)</td><td>(474.51)</td><td>(474.51)</td></tr><tr><td>Adjustment of Tax, GST and others which in audited with Reserve & Surplus, now regrouped in respective head</td><td>294.39</td><td>294.39</td><td>191.60</td></tr><tr><td>Rectification of errors in consolidation of associates as of 31st March 2024</td><td>649.82</td><td>-</td><td>-</td></tr><tr><td>Wrong Derecognition of loss of Associates & Subsidiary in March 2024</td><td>(20.69)</td><td>(20.69)</td><td>-</td></tr><tr><td>Net Adjustment in Reserve & Surplus account (b)</td><td>(0.89)</td><td>(1,542.68)</td><td>(1,206.05)</td></tr><tr><td><strong>Total Reserve & Surplus as per Restated Financial Statement: (a+b)</strong></td><td><strong>18,837.03</strong></td><td><strong>16,023.94</strong></td><td><strong>12,579.02</strong></td></tr></tbody></table>

196